Market Overview

Platelet BioGenesis Moves to New Cambridge Lab Space to Support Continued Growth


Move to Nest.Bio Labs comes as company advances its program to
commercialize a donor-independent source of lifesaving platelets

Platelet BioGenesis (PBG), the leader in the production of functional
human platelets (PLTs+™) from stem cells and the development of
platelet-based therapeutics, announced it has moved into brand new lab
space in Cambridge, MA. Located next to MIT, the newly renovated
property puts Platelet BioGenesis in the heart of the most dynamic
biotech cluster in the world.

Platelet BioGenesis' new space is located in Nest.Bio Labs, a unique
incubator space that hosts a growing number of innovative early-stage
life science companies.

"We are thrilled to have Platelet BioGenesis as one of our founding
tenants," commented James Weis, CEO of Nest.Bio Labs. "As pioneers in
cell therapy, this company is a standout in our carefully cultivated
community of trailblazing ventures."

The new lab space, located at 325 Vassar Street, will accommodate PBG's
aggressive growth, which has seen the startup more than double in size
in less than a year. The 14,000-square-foot facility includes more than
50 oversized wet lab benches as well as a state-of-the-art tissue
culture and microscopy suites to support R&D operations.

"Platelet BioGenesis' move to Cambridge will accelerate our continued
growth as we scale our novel method of generating disease-free,
GMP-compliant, donor-independent, functional human platelets," said Ryan
Chappell, lab manager of Platelet BioGenesis. "We anticipate hiring
additional scientific and administrative personnel as we advance to the

Added Jonathan Thon, Ph.D., PBG co-founder and CEO, "Surrounding
ourselves with other growing life science companies in the Nest.Bio
incubator adds to the excitement of our rapid progress. Platelet
BioGenesis' goal is to alleviate the chronic shortage of platelets for
transfusion to cancer patients, those undergoing surgery, and others in
need of these life-saving cells."

About Platelet BioGenesis
Platelet BioGenesis is a
venture-backed, development stage biotech company creating the world's
first donor-independent source of platelets to address the chronic
platelet shortage that affects patients worldwide. The company has
developed and patented a scalable cGMP-compliant process to generate
platelets from human induced pluripotent stem cells. Based in Cambridge,
Mass., Platelet BioGenesis is also developing designer platelets
(PLTs+™), a new class of therapeutics to treat cancer and other
life-threatening diseases. The company was spun out of Harvard
University and has received funding from the Massachusetts
Life Sciences Center
, the National
Institutes of Health
and the U.S.
Department of Defense
. Learn more at
and follow us on Twitter @plateletbiogen.

About Nest.Bio Labs
Launched in partnership with pioneering
entrepreneurs and investors, Nest.Bio
is a shared community designed specifically to hatch
revolutionary biotechnology ventures. Nest.Bio Lab's 14,000-square-foot
facility includes turnkey laboratory services, state-of-the-art tissue
culture and microscopy suites, and extensive core equipment and
instrumentation. Located next to MIT in the international biotechnology
hub of Cambridge, Massachusetts, Nest.Bio Labs brings together a
carefully selected group of tenants and partners to create a complete
life sciences incubation ecosystem.

View Comments and Join the Discussion!